07:00 , Oct 7, 2013 |  BC Week In Review  |  Company News

Enteris, Nordic Bioscience deal

Enteris BioPharma granted Nordic Bioscience's KeyBioScience subsidiary rights to Enteris' Peptelligence oral drug delivery and recombinant manufacturing technologies for the development of a family of metabolic peptides. Enteris will also become the exclusive provider of...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Company News

Enteris BioPharma Inc. management update

Brian Zietsman as president and CFO, formerly CFO of Unigene Enteris BioPharma Inc. , Boonton, N.J.   Business: Drug delivery   Hired: Nozer Mehta as CSO, formerly CSO of Unigene Laboratories Inc. ; and  ...
07:00 , Jul 1, 2013 |  BioCentury  |  Finance

2Q Stock Wrap-Up: If it ain't broke

Despite one segment that finished the second quarter in the red, all market cap groups are still up for the year. In 2Q13, the sector was led by large caps, which closed up 4%, marking...
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

Unigene deal

On April 25, four of investor Victory Park Credit's affiliates acquired Unigene's oral drug delivery assets in a public auction in exchange for the satisfaction and discharge of $15 million outstanding under senior secured notes....
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Unigene drug delivery, musculoskeletal news

Unigene reduced headcount by about 21 (40%) to 31 to conserve capital and extend its cash runway. The company said the cuts came from manufacturing of its osteoporosis drug Fortical calcitonin and recombinant calcitonin production...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Financial News

Unigene completes private placement of senior notes

Unigene Laboratories Inc. (OTCBB:UGNE), Boonton, N.J.   Business: Drug delivery, Musculoskeletal   Date completed: 4/8/13   Type: Private placement of senior notes   Raised: $750,000   Shares outstanding prior: 96 million   Investors: Victory Park...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Financial News

Unigene financial update

Unigene disclosed in its 2012 earnings that it will immediately need to obtain additional financing to fund operations, address its debt and restructure its balance sheet. The company said if it is unable to obtain...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Calcitonin salmon regulatory update

FDA's Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee voted 12-9 that the overall benefit-risk assessment does not support the continued marketing of calcitonin salmon to treat osteoporosis...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

Calcitonin salmon regulatory update

FDA's Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee will meet on March 5 to discuss whether the benefit of calcitonin salmon for postmenopausal osteoporosis outweighs a potential...
01:59 , Jan 15, 2013 |  BC Extra  |  Company News

FDA to discuss risk/benefit of calcitonin salmon for osteoporosis

FDA's Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee will meet on March 5 to discuss whether the benefit of calcitonin salmon for postmenopausal osteoporosis outweighs a potential...